PRP Eye Drop Composition for Dry Eye and Ocular Surface Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dry eye disease (DED) are often ineffective, time-consuming, expensive, or difficult for patients to tolerate, and do not address the heterogenous nature of DED symptoms, while also failing to promote eyelash growth and provide ocular health benefits.
Innovation Solution
A composition comprising platelet rich plasma (PRP), Acetylcysteine, Vitamin C, Vitamin B12, saline, hyaluronic acid, and cyclosporine A, optionally with ferulic acid, is administered to treat DED and promote eyelash growth, utilizing a PRP processing kit for preparation and delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If currently available treatments for dry eye disease are used, then some DED symptoms may be temporarily relieved, but the treatments are often ineffective for moderate to severe cases, time-consuming, expensive, or difficult for patients to tolerate
Solution Approach 1:
The patent combines multiple active ingredients (cyclosporine, hyaluronic acid, vitamin B12, vitamin C, acetylcysteine, ferulic acid) into a single composite eye drop formulation. This composite approach addresses the heterogenous nature of DED by providing multi-target therapy, improving reliability for moderate to severe cases while maintaining ease of use through a single daily administration.
Solution Approach 2:
The patent merges multiple therapeutic functions into one formulation: anti-inflammatory action (cyclosporine), lubrication (hyaluronic acid), antioxidant protection (vitamins C and E, acetylcysteine, ferulic acid), and nutritional support (vitamin B12). This consolidation improves treatment reliability while enhancing patient convenience by eliminating the need for multiple separate treatments.
2Adaptability or versatility
If currently available treatments are used, then some relief may be provided, but they fail to address the heterogenous nature of DED symptoms and do not promote eyelash growth or provide comprehensive ocular health benefits
Solution Approach 1:
The patent creates a universal treatment that addresses multiple aspects of ocular health simultaneously: treating dry eye symptoms through anti-inflammatory and lubricating actions, promoting eyelash growth through nutrient delivery, and providing antioxidant protection. This multi-functional formulation enhances adaptability to heterogeneous DED presentations without requiring separate treatments for each condition.
3Reliability
If oral antioxidant vitamins are taken to protect against UV damage, then antioxidant protection is delivered to the retina and macula, but the corneal surface does not receive direct circulation from the blood supply
Solution Approach 1:
The patent uses topical eye drops as an intermediary delivery system that bypasses the limitation of oral administration. The eye drop formulation containing antioxidants (vitamin C, vitamin E, acetylcysteine, ferulic acid) is applied directly to the ocular surface, enabling these compounds to reach the corneal surface through the tear film without relying on blood circulation. This resolves the contradiction by providing a direct delivery pathway to the target tissue.
Data Source
AI summary
A therapeutic composition, PRP assembly kit and method for treatment of dry eye disease administered via an eye drop applicator or via a syringe or cannula to the eye of a patient.